- InSite Vision (OTCQB:INSV) completes the filing of its New Drug Application (NDA) for BromSite for the treatment of inflammation and prevention of pain in cataract surgery. The completion of the NDA filing satisfies InSite's obligation under its merger agreement with QLT. The transaction is expected to close in Q3.
- BromSite is a low dose (0.075%) bromfenac ophthalmic solution. Bromfenac is a non-steroidal anti-inflammatory drug (NSAID).